At the 3rd C5 Forum on Biosimilars in London on Wednesday, a panel of lawyers and regulatory experts discussed the lie of the land for biosimilars.
Novartis Pharmaceuticals has filed a lawsuit against US drug manufacturer Roxane Laboratories disputing an application for a schizophrenia drug.
India is considering altering its requirements for filing drug patents in a bid to create more transparency in the pharmaceutical market, it has been claimed.
The US Supreme Court has refused a request from Teva to stay an appeals court order, meaning the pharmaceutical company will lose exclusivity on Copaxone in May next year, rather than in 2015.
Aaron Cooper, chief counsel for IP and antitrust law in the US Senate Judiciary Committee, is to join law firm Covington & Burling LLP.
US pharmaceutical company Forest Laboratories and drug company Actavis have settled a legal dispute over a patent protecting blood pressure drug Bystoli (nebivolol).
The UK Patents Court has referred four questions to the CJEU seeking clarification on how the SPC Regulation should be interpreted in relation to drug products made of a combination of active ingredients.
The Indian Patent Office has rejected an application for a compulsory licence that was filed by domestic drug maker BDR Pharmaceuticals.
Mr Justice Arnold has refused to recuse himself from a patent trial after he was accused of being conflicted by an expert witness.
Patent litigator Jonathan Radcliffe has left Mayer Brown to become partner at Charles Russell LLP.